Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 2, 2000, Pages 294-303

  Pfeltz, Richard F ^a   Singh, Vineet K ^a   Schmidt, Jennifer L ^a   Batten, Michael A ^a   Baranyk, Christopher S ^a   Nadakavukaren, Matthew J ^a   Jayaswal, Radheshyam K ^a   Wilkinson, Brian J ^a  

^a ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLYSIN; GLYCOPEPTIDE; LYSOSTAPHIN; METICILLIN; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLYSIS; BACTERIAL CELL WALL; BACTERIAL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; GENETIC RESISTANCE; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; ANTIGENS, SURFACE; BACTERIOLYSIS; CELL WALL; CULTURE MEDIA; HUMANS; LYSOSTAPHIN; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0033972069     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.2.294-303.2000     Document Type: Article

References (35)

1. Biavasco, F., E. Giovanetti, M. P. Montanari, R. Lupidi, and P. E. Varaldo. 1991. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J. Antimicrob. Chemother. 27:71-79.
2. Billot-Klein, D., D. Shlaes, D. Bryant, D. Bell, R. Legrand, L. Gutmann, and J. van Heijenoort. 1997. Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycin. J. Bacteriol. 179:4684-4688.
3. Brown, D. F. J., and P. E. Reynolds. 1980. Intrinsic resistance to β-lactam antibiotics in Staphylococcus aureus. FEBS Lett. 76:275-278.
4. Centers for Disease Control. 1997. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan. 1996. Morbid. Mortal. Weekly Rep. 46:624-626.
5. Centers for Disease Control. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:813-815.
6. Daum, R. S., S. Gupta, R. Sabbagh, and W. M. Milewski. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis. 166:1066-1072.
7. Debbia, E., P. E. Varaldo, and G. C. Schito. 1986. In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin. Antimicrob. Agents Chemother. 30:813-815.
8. de Lencastre, H. M., B. L. M. DeJonge, P. R. Matthews, and A. Tomasz. 1994. Molecular aspects of methicillin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 33:7-24.
9. Foster, S. J. 1995. Molecular characterization and functional analysis of the major autolysin of Staphylococcus aureus 8325/4. J. Bacteriol. 177:5723-5725.
10. Gustafson, J. E., B. Berger-Bächi, A. Strassle, and B. J. Wilkinson. 1992. Autolysis of methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 36:566-572.
11. Hanaki, H., K. Kuwahara-Arai, S. Boyle-Vavra, R. S. Daum, H. Labischinski, and K. Hiramatsu. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209.
12. Hanaki, H., H. Labischinski, V. Inaba, N. Kondo, H. Murakami, and K. Hiramatsu. 1998. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 42:315-320.
13. Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Res. Updates 1:135-150.
14. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
15. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
16. Kaatz, G. W., S. M. Seo, N. J. Dorman, and S. A. Lerner. 1990. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J. Infect. Dis. 162:103-108.
17. Mani, N., L. M. Baddour, D. Q. Offutt, U. Vijaranakul, M. J. Nadakarukaren, and R. K. Jayaswal. 1994. Autolysis-defective mutant of Staphylococcus aureus: pathological considerations, genetic mapping, and electron microscopic studies. Infect. Immun. 62:1406-1409.
18. Mani, N., Tobin, P., and R. K. Jayaswal. 1993. Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis. J. Bacteriol. 175:1493-1499.
19. Moreira, B., S. Boyle-Vavra, B. L. M. DeJonge, and R. S. Daum. 1997. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1788-1793.
20. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
22. Noble, W. C., Z. Virani, and R. G. A. Cree. 1992. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 93:195-198.
23. Oshida, T., M. Sugai, H. Komatsuzawa, Y.-M. Hong, H. Suginaka, and A. Tomasz. 1995. A Staphylococcus aureus autolysin that has an N-acetylmuramoyl-L-alanine amidase domain and an endo-N-acetylglucosaminidase domain: cloning, sequence analysis, and characterization. Proc. Natl. Acad. Sci. USA 92:285-289.
24. Paulsen, I. T., N. Firth, and R. A. Skurray. 1997. Resistance to antimicrobial agents other than β-lactams, p. 175-212. In K. B. Crossley and G. L. Archer (ed.), The staphylococci in human disease. Churchill Livingstone, New York, N.Y.
25. Ramadurai, L., and R. K. Jayaswal. 1997. Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus. J. Bacteriol. 179:3625-3631.
26. Reifsteck, F., S. Wee, and B. J. Wilkinson. 1987. Hydrophobicity-hydrophilicity of staphylococci. J. Med. Microbiol. 24:65-73.
27. Rotun, S. S., V. McMath, D. J. Schoonmaker, P. S. Maupin, F. C. Tenover, B. C. Hill, and D. M. Ackman. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. 5:147-149.
28. Sabath, L. D., S. J. Wallace, K. Byers, and I. Toftegaard. 1974. Resistance of Staphylococcus aureus to penicillins and cephalosporins: reversal of intrinsic resistance with some chelating agents. Ann. N. Y. Acad. Sci. 236:435-443.
29. Schwalbe, R. S., J. T. Stapleton, and P. H. Gilligan. 1987. Vancomycin-resistant staphylococcus. N. Engl. J. Med. 317:766-768.
30. Sieradzki, K., R. B. Roberts, S. W. Haber, and A. Tomasz. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-523.
31. Sieradzki, K., and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566.
32. Sieradzki, K., and A. Tomasz. 1998. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis. Microb. Drug Res. 4:159-168.
33. Tanaka, M., N. Wada, S. M. Kurosaka, M. Chiba, K. Sato, and K. Hiramatsu. 1998. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. J. Antimicrob. Chemother. 42:552-553.
34. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 34:1020-1027.
35. Wenzel, R. P., M. D. Nettleman, R. N. Jones, and M. A. Pfaller. 1991. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am. J. Med. 91(Suppl. 3B):2215-2275.